The NIH Clinical Centre in Bethesda has started recruiting patients for a new phase II clinical trial to test the safety and efficacy of Everolimus in BHD patients with renal tumours and sporadic chromophobe renal tumours. More details on inclusion and exclusion criteria can be found on the NIH Clinical Centre website.

Patients interested in the trial should contact Martha Ninos (mninos@mail.nih.gov).